Literature DB >> 15585614

Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.

David R Colnot1, Eline J C Nieuwenhuis, Dirk J Kuik, C René Leemans, Janny Dijkstra, Gordon B Snow, Guus A M S van Dongen, Ruud H Brakenhoff.   

Abstract

PURPOSE: Despite improvements in locoregional treatment of head and neck squamous cell carcinoma (HNSCC), local and distant failure rates remain high. The strongest prognostic indicator of HNSCC is the presence of lymph node metastases in the neck, but the value of this indicator has limitations when using for the individual patient. The presence of micrometastatic cells in bone marrow has been shown to be a putative prognostic indicator in HNSCC and other epithelial malignancies, which might allow more accurate staging and selection of patients for whom adjuvant or experimental therapy is recommended. The gene encoding the E48 antigen is selectively expressed by HNSCC, and the detection of E48 transcripts in bone marrow by reverse transcription-polymerase chain reaction (RT-PCR) presumably represents the presence of micrometastatic cells. The purpose of this study was to determine the association between the presence of micrometastatic cells in bone marrow of HNSCC patients and clinical outcome. EXPERIMENTAL
DESIGN: A total of 162 patients treated surgically for primary HNSCC underwent a single bone marrow aspiration from the upper iliac crest for detection of micrometastatic cells using E48 RT-PCR. In total, 139 patients were evaluable. The primary statistical endpoints were disease-free survival and distant metastasis-free survival. In addition, bone marrow samples of 30 noncancer controls were evaluated.
RESULTS: E48 RT-PCR indicated the presence of micrometastatic cells in the bone marrow in 56 of 139 (40%) of the HNSCC patients and 0 of 30 of the noncancer controls (P < 0.0001). The presence of micrometastatic cells had no significant influence on disease-free survival or distant metastasis-free survival for the whole group of HNSCC patients (P = 0.1460 and P = 0.2912, respectively). For patients with >or=2 lymph node metastases, however, the presence of micrometastatic cells was associated with a poor distant metastasis-free survival (P = 0.0210).
CONCLUSIONS: The presence of micrometastatic cells in bone marrow of HNSCC patients with >or=2 lymph node metastases is correlated with a poor distant metastasis-free survival. In this subgroup of HNSCC patients, E48 RT-PCR seems to be a valuable tool to identify patients who are at increased risk for development of distant metastases and therefore might benefit from experimental adjuvant systemic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585614     DOI: 10.1158/1078-0432.CCR-04-1090

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Authors:  Hongyan Yuan; Geeta Upadhyay; Yuzhi Yin; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-28

Review 2.  Current potential and limitations of molecular diagnostic methods in head and neck cancer.

Authors:  Magdy E Mahfouz; Juan P Rodrigo; Robert P Takes; Mohamed N Elsheikh; Alessandra Rinaldo; Ruud H Brakenhoff; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06       Impact factor: 2.503

Review 3.  Prognostic biological features in neck dissection specimens.

Authors:  Julia A Woolgar; Asterios Triantafyllou; James S Lewis; Jennifer Hunt; Michelle D Williams; Robert P Takes; Lester D R Thompson; Pieter J Slootweg; Kenneth O Devaney; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-15       Impact factor: 2.503

4.  Genetic reprogramming of tumor cells by zinc finger transcription factors.

Authors:  Pilar Blancafort; Emily I Chen; Beatriz Gonzalez; Sharon Bergquist; Andries Zijlstra; Daniel Guthy; Arndt Brachat; Ruud H Brakenhoff; James P Quigley; Dirk Erdmann; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

5.  In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.

Authors:  M Nestor; M Persson; G A M S van Dongen; H J Jensen; H Lundqvist; M Anniko; V Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-19       Impact factor: 9.236

6.  Micrometastasis of hypopharyngeal cancer.

Authors:  P Sabljak; P Pesko; D Stojakov; M Micev; E Keramatollah; D Velickovic; O Skrobic; V Sljukic; A Djikic-Rom
Journal:  Langenbecks Arch Surg       Date:  2014-05-11       Impact factor: 3.445

Review 7.  Detection of lymph node micrometastases in patients with squamous carcinoma of the head and neck.

Authors:  Alfio Ferlito; Alessandra Rinaldo; Kenneth O Devaney; Koh-ichi Nakashiro; Hiroyuki Hamakawa
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-04       Impact factor: 2.503

8.  Circulating tumor cells in head and neck cancer: clinical impact in diagnosis and follow-up.

Authors:  N Möckelmann; S Laban; K Pantel; R Knecht
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-14       Impact factor: 2.503

Review 9.  Squamous cell carcinoma of the oral cavity and circulating tumour cells.

Authors:  Johannes Wikner; Alexander Gröbe; Klaus Pantel; Sabine Riethdorf
Journal:  World J Clin Oncol       Date:  2014-05-10

10.  Molecular diagnosis of minimal residual disease in head and neck cancer patients.

Authors:  A Peggy Graveland; Boudewijn J M Braakhuis; Simone E J Eerenstein; Remco de Bree; Elisabeth Bloemena; Michiel de Maaker; Michiel W M van den Brekel; Frederike Dijk; Wilma E Mesker; Hans J Tanke; C Rene Leemans; Ruud H Brakenhoff
Journal:  Cell Oncol (Dordr)       Date:  2012-09-04       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.